Bristol-Myers Sees Five Meds Cushioning The Fall Off The Patent Cliff
Executive Summary
Just two days after being named the next chief executive officer at Bristol-Myers Squibb, Lamberto Andreotti told a crowd of Wall Street analysts that the drug maker is on track to launch five medicines by 2012 - the year two key drugs go off patent - and vowed that strong financial growth will resume by 2014
You may also be interested in...
Bristol/AstraZeneca Roll Out Onglyza Post-Market Cardio Study
The Phase IV commitment to study cardio risk is part of saxagliptin's approval, but the partners are also looking for data to support a claim of cardioprotective effect.
Bristol/AstraZeneca Roll Out Onglyza Post-Market Cardio Study
The Phase IV commitment to study cardio risk is part of saxagliptin's approval, but the partners are also looking for data to support a claim of cardioprotective effect.
BMS CEO Jim Cornelius to Retire; Andreotti Named CEO
Lamberto Andreotti, currently president, was the front-runner in a year-long, three-way race to replace Cornelius.